LONDON (AFX) - Elan Corporation PLC and Biogen Idec Inc said they have had positive two-year results from the two Phase III clinical trials evaluating TYSABRI (natalizumab) for patients with relapsing forms of multiple sclerosis (MS), as well as data from the comprehensive safety evaluation.
Data from AFFIRM and SENTINEL, among the largest ever Phase III MS trials, provide compelling evidence of the benefit of TYSABRI, the companies said.
Currently available MS therapies often do not adequately control the disease for many patients, creating a significant unmet need that TYSABRI may help address, they added. newsdesk@afxnews.com slm COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content,inculding by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
© 2006 AFX News
